Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab
Abstract. Background:. With current chemotherapy treatment, >90% of survival has been obtained for Burkitt lymphoma (BL). In this study, the demographic characteristics and treatment outcomes are presented for 78 children in China with central nervous system-positive (CNS+) BL. Methods:. This ret...
Main Authors: | Shuang Huang, Lin Jin, Jing Yang, Yan-Long Duan, Meng Zhang, Chun-Ju Zhou, Yong-Hong Zhang, Peng Lyu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2021-06-01
|
Series: | Chinese Medical Journal |
Online Access: | http://journals.lww.com/10.1097/CM9.0000000000001386 |
Similar Items
-
Rituximab and Immune Molecule Modulation in Burkitt’s Lymphoma Cell Lines
by: Rebecca Quilty, et al.
Published: (2019-05-01) -
The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
by: Ruben Van Dijck, et al.
Published: (2021-04-01) -
Central Nervous System Burkitt Lymphoma in a child (A case report).
by: Hassan Mahmoodi Nesheli
Published: (2015-09-01) -
HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era
by: J. A. Rodrigo, et al.
Published: (2012-01-01) -
Linfoma de Burkitt Burkitt lymphoma
by: Fernando Sierra Arego, et al.
Published: (2012-03-01)